| dc.creator |
US National Cancer Institute |
|
| dc.date |
2004-11-25T12:15:28Z |
|
| dc.date |
2004-11-25T12:15:28Z |
|
| dc.date |
2003-02-01 |
|
| dc.date |
2004-11-25T12:15:28Z |
|
| dc.date.accessioned |
2022-05-24T18:31:10Z |
|
| dc.date.available |
2022-05-24T18:31:10Z |
|
| dc.identifier |
NSC185 |
|
| dc.identifier |
http://www.dspace.cam.ac.uk/handle/1810/1740 |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/119412 |
|
| dc.format |
7894 bytes |
|
| dc.format |
7209 bytes |
|
| dc.format |
chemical/x-cml |
|
| dc.format |
chemical/x-cml |
|
| dc.language |
en_GB |
|
| dc.publisher |
Unilever Center for Molecular Informatics, Cambridge University |
|
| dc.title |
NSC185 |
|
| dc.title |
.beta.-[2-(3, 5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide |
|
| dc.title |
Acti-dione BR |
|
| dc.title |
Acti-Aid |
|
| dc.title |
Actidion |
|
| dc.title |
Actidione |
|
| dc.title |
Actidione PM |
|
| dc.title |
Actidone |
|
| dc.title |
Actispray |
|
| dc.title |
ACTIDIONE |
|
| dc.title |
Cicloheximide |
|
| dc.title |
Cyclohemimide |
|
| dc.title |
Cyclohexamide |
|
| dc.title |
Cycloheximide |
|
| dc.title |
CBC 500046 |
|
| dc.title |
CX |
|
| dc.title |
CYCLOHEXIMIDE |
|
| dc.title |
Glutarimide, 3-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]- (VAN 8CI) |
|
| dc.title |
Glutarimide, 3-[2-(3, 5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]- (VAN8CI) |
|
| dc.title |
Hizarocin |
|
| dc.title |
Kaken |
|
| dc.title |
Naramycin |
|
| dc.title |
Naramycin A |
|
| dc.title |
Neocycloheximide |
|
| dc.title |
NARAMYCIN A |
|
| dc.title |
NSC-185 |
|
| dc.title |
TZA |
|
| dc.title |
U 4527 |
|
| dc.title |
WLN: T6VMVTJ E1YQ- BL6VTJ D1 F1 |
|
| dc.title |
2, 6-Piperidinedione, 4-[2-(3, 5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-, [1S-[1.alpha.(S*), 3.alpha.,5.beta.]]- (9CI) |
|
| dc.title |
3-[2-(3, 5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide |
|
| dc.title |
4-[2-(3, 5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-2,6-piperidinedione |
|
| dc.type |
Chemical Structures |
|